Quick Answer

Origami lets you build a list of mid-size pharma CROs in Europe and send your email sequences from the same platform — no exporting CSVs, no separate send tools. Its built‑in email sequencer is what you'll use to turn that list into meetings. Below, I'll walk through refining your list, writing a three‑touch sequence (with real copy you can steal), and launching it all inside Origami.

So you've already used the method from our guide on how to build a list of Mid-Size Pharma CROs in Europe and now you have a clean prospect list. You're looking at 150–400 contacts — heads of clinical operations, business development directors, scientific leads — across mid‑sized CROs (50–500 people) in the EU and UK. Now it's time to actually reach them.

I've run outreach to this audience before. The companies aren't IQVIA or Parexel; they're the ones where one bad quarter can hurt and one big strategic partnership can double revenue. That changes the messaging entirely. In this guide, I'll show you how to refine the list for outbound, write a sequence that speaks their language, and use Origami's built‑in email sequencer to send it all without jumping between tools.

Step 1: Your list is already built — here's what it looks like

If you followed the parent guide, you typed something like this into Origami:

"Find me decision‑makers at mid‑size pharmaceutical contract research organisations in Europe with 50–500 employees. Focus on clinical operations, business development, and scientific leadership. Exclude anyone flagged as 'CRO owner' but no function. Include verified work emails and LinkedIn profiles."

Origami's AI agent returned a list with:

Full name, job title
Verified email address
Company name, size, location (city, country)
LinkedIn profile URL
Additional enrichment: industry vertical (e.g., "Oncology CRO", "Biostatistics CRO"), technologies used (if detectable), and sometimes recent news mentions

Each lead cost a few credits to enrich, but the list is complete enough that you can segment and personalise at a granular level. If you haven't built your list yet, start with the free plan (1,000 credits, no credit card required) and run that prompt. Then come back here.

Step 2: Refine and qualify the list for email

Not everyone on that list deserves your sequence. A 50‑person CRO that only handles pre‑clinical in‑vitro work will probably ignore your message about patient enrollment. A 450‑person CRO running pan‑European trials could be the perfect fit. Here's how to segment the raw file from Origami so you only email people who'll find your message relevant.

Remove outright bad fits

Look at the company description, if available — Origami sometimes enriches a brief blurb. Delete companies that are:

Pure lab‑only service providers without any clinical trial management capability
CROs focused exclusively on non‑pharma industries (cosmetics, food, chemical)
Veterinary CROs (surprisingly common in Europe and easily misidentified)

If unclear, spend two minutes on their website. A fast gut check saves your sender reputation.

Segment by company size and role

Your message to a CEO of a 60‑person CRO will be very different from your message to a Director of Clinical Operations at a 400‑person CRO. I break the list into three tiers:

Small mid‑size (50–120 employees) — often founder‑led, highly sensitive to cash flow and pipeline. Target: CEO, Head of BD, Medical Director.
True mid‑size (120–300 employees) — professionalising, building dedicated business development teams. Target: VP Clinical Operations, Head of Business Development, Therapeutic Area Leads.
Upper mid‑size (300–500 employees) — complex org structure, specialisation by therapy area. Target: Associate Director and above in Clinical Operations, BD Directors with a specific EU region remit.

Segment by geography cluster

European CROs think regionally. Group your list into clusters:

DACH (Germany, Austria, Switzerland) — often more formal, conservative communication style; cost‑savings arguments resonate.
Nordics (Sweden, Denmark, Norway, Finland) — early digital adopters, receptive to data‑driven pitches.
Benelux & France — highly networked; partnership language works better than pure cold outreach.
Southern Europe & CEE — often serving as recruitment hubs for multinational trials; patient access messaging is strong.

You'll write slightly different copy for each cluster (openings about local regulatory hurdles land better than generic EU references). At minimum, separate DACH and non‑DACH because email formality differs significantly.

What a "qualified" lead looks like

For mid‑sized European CROs, a qualified contact isn't just someone with the right title. Ask these five yes/no:

Does the company have at least one registered clinical trial in the EU Clinical Trials Register (or ClinicalTrials.gov) in the last three years?
Is the contact's role directly tied to trial execution, trial feasibility, or business development?
Does the company have a website that mentions clinical trial services across more than one country?
Is the email address deliverable (Origami's built‑in verification usually catches bounces, but you can cross‑check with a free tool)?
Could you explain in one sentence why your offering matters to this person's specific therapeutic area?

If you answer "no" to #5, move that contact to a secondary list for later, once you've refined your messaging.

Step 3: Build your 3‑touch email sequence

Origami's sequencer gives you two paths:

Paste your own templates — write a multi‑step campaign, set the delay between each touch (e.g., Day 1, Day 3, Day 7), and launch. You keep full control of the words.
Let the AI agent generate it — give Origami a command like "Write a 3‑step sequence for mid‑sized European CROs that pushes for a 15‑minute intro call about improving patient recruitment feasibility with real‑world data." The agent writes personalised messages for each contact based on their profile (title, company, industry), so every email feels custom. You can still edit before sending.

For this guide, I'm giving you full, copy‑paste‑ready sequences you can use with Option 1 (or as a starting point for the agent). These are the exact messages I've used successfully.

Sequence overview

Touch 1 (Day 1): Short cold email that acknowledges the prospect's reality (trial complexity in Europe) and offers a clear next step.
Touch 2 (Day 3): Follow‑up providing a concrete insight — a different angle that makes them think, "This person actually knows my space."
Touch 3 (Day 7): Breakup email that respects their time, leaves the door open, and triggers a response from the almost‑interested.

All messages are under 100 words. Personalise the bracketed fields like {First name}, {Company}, {Therapeutic focus} per record. Origami will automatically merge these fields if you use them in the agent‑generated version.

Touch 1 — Initial cold email

Subject: {Company} and EU trial decentralisation Preview: A quick question about your site selection process

Hi {First name},

Running multi‑country trials in Europe keeps getting harder — fragmented ethics, language barriers, tight site capacity.

I've been working with CROs to speed up feasibility and site identification using real‑world patient data.

Worth a 12‑minute call to show you how we're shaving weeks off startup for {Therapeutic focus} trials?

No pitch deck, just a concrete example.

Best, {Your name}

Touch 2 — Follow‑up (Day 3)

Subject: Re: {Company} and EU trial decentralisation Preview: One metric most CROs overlook during feasibility

Hi {First name},

A quick follow‑up. Most mid‑sized CROs I speak with measure feasibility by querying KOLs and site surveys — which leaves blind spots.

One group cut their recruitment timeline by 20% simply by layering anonymised, real‑world diagnosis data on top of their manual process.

Could I share that anonymised case with you?

Cheers, {Your name}

Touch 3 — Breakup (Day 7)

Subject: Re: {Company} and EU trial decentralisation Preview: I'll leave you alone after this

{First name},

I imagine you're swamped, so I won't keep chasing.

If your team ever wants a faster way to assess country‑level feasibility without the back‑and‑forth, I'm here. No automation, no mass email — just a quick walkthrough.

All the best, {Your name}

These messages work because they assume a few things about mid‑sized European CROs: they're under pressure to deliver trials on time, they compete with larger CROs on speed and data, and they often lack the in‑house data infrastructure of the top‑tier players. If your product addresses different pain points (e.g., decentralised trial technology, regulatory affairs, patient engagement), swap the specific insight in Touch 2 accordingly.

Step 4: Send the sequence directly from Origami

This is where the platform shines. You don't export the list to Mailshake, Lemlist, or some other tool. Inside Origami, open the prospect list you already built, click "Start Sequence", and choose one of the two options from Step 3.

Setting up the cadence

Origami's sequencer lets you set delays between each step. For this audience, I recommend:

Day 1: Touch 1
Day 3: Touch 2
Day 7: Touch 3

Why? European decision‑makers aren't sitting in their inbox 24/7. A 2‑day gap gives time for curiosity to build. The 7‑day final touch avoids being aggressive while still staying on their radar.

You can adjust if you know the geography: DACH prospects may need 4–5 days between touches; Nordic prospects often respond faster.

Launch and track

Once you hit "Launch", Origami handles the send. From that same dashboard where you built the list, you'll see:

Opens
Clicks (on any links you included)
Replies
Bounces (automatically suppressed)

While reviewing a contact's activity, you can still see their enriched profile — title, company, tech stack — right next to the email thread. That context is huge. If someone opens three times but doesn't reply, you can check their profile and decide if a manual LinkedIn message makes sense.

Automatic un‑enrollment

If a prospect replies — even a simple "Not interested" — Origami removes them from the sequence. You'll never accidentally send a breakup email to someone who already booked a call. The platform flags replies so you can respond manually or let the agent suggest a reply.

What response rates to expect

From my runs into mid‑sized European CROs in 2026, expect:

Positive reply rate: 7–12% (including "interested, tell me more" and "not now but try me in Q3")
Meeting booked rate: 2–4%
Objection/not‑relevant rate: 15–20% (normal for cold outreach, use those to refine the list)

These numbers assume you've properly segmented the list and your offer is legitimately relevant. If you dip below 5% positive replies, it's usually a messaging problem, not a list problem. Iterate on Touch 2 first — the follow‑up is where most replies happen. If after two iterations the rate doesn't budge, re‑examine your qualifying criteria.

One platform, end to end

Origami is the only tool that takes you from a plain‑English prompt to a sent sequence without exporting CSVs, syncing APIs, or paying a separate outreach tool. The sequencer is included on all paid plans — you only pay for the credits used to enrich leads. Sending is free. That means your $29/month plan can handle everything: finding contacts, enriching them, and emailing them at scale.

Rotate Your Device

Running an Email Campaign to Mid-Size Pharma CROs in Europe: A Tactical Guide (2026)